Provention Bio, Inc., a company aimed at intercepting and preventing immune-mediated diseases, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application for coxsackievirus B (CVB) vaccine to prevent or treating type 1 diabetes.
Provention Bio is developing PRV-101 as a vaccine for acute coxsackie virus infection and potentially as the first-ever vaccine designed to prevent T1D.
Epidemiological and experimental studies indicate that approximately half of all T1D cases could be triggered by a CVB infection in early childhood.
Based on this research, which was recently the subject of a peer-reviewed paper in Expert Review of Vaccines, Provention Bio is developing PRV-101 to reduce the onset of T1D by vaccinating at-risk populations against CVB infection.
PRV-101 is currently in an IND-enabling stage prior to the initiation of first-in-human studies.
“This Notice of Allowance from the USPTO is a significant advancement in the ongoing development of PRV-101 and emboldens Provention’s vision to develop a vaccine for CVB that could potentially prevent up to 50% of worldwide T1D cases,” said Ashleigh Palmer, Provention Bio’s Co-Founder and Chief Executive Officer. “As we advance PRV-101 towards the clinic, we will continue to aggressively pursue opportunities to strengthen the intellectual property estate surrounding this technology and the use of a polyvalent CVB vaccine to prevent T1D,” he added.